Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Clinical trial NCT00472693 · COMPLETED
Trial details
- NCT number
- NCT00472693
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-05-01
- Primary completion
- 2011-04-01
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.